Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for aggressive lung cancer: targeted drug trial opens

NCT ID NCT06758700

Recruiting now Disease control Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called teniposide in people with a fast-growing type of lung cancer (extensive-stage small cell lung cancer) that has a specific gene change (c-Myc-driven). The cancer must have gotten worse after standard treatments. The goal is to see if teniposide can shrink tumors or slow the disease. About 15 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung disorder lung neoplasm neoplasm of thorax small cell lung carcinoma Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) LUNG DISEASES LUNG NEOPLASMS THORACIC NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Pulmonary Hospital, Shanghai, China

    RECRUITING

    Shanghai, Shanghai Municipality, 200331, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.